Scienture Holdings, Inc. announced a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at an offering price of $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million.
Offering Details
3,225,000 shares of common stock to be purchased at $1.20 per share.
Proceeds
Expected gross proceeds of approximately $3.9 million.
Closing Date
The offering is expected to close on August 15, 2025.
Placement Agent
Maxim Group LLC is acting as the sole placement agent.
- The offering is part of Scienture's strategy to raise funds for its pharmaceutical operating companies.
- The securities purchase agreement indicates investor confidence in Scienture's novel specialty products.
- The successful offering will enable Scienture to further develop and bring unique products to market.
The securities purchase agreement marks a significant step for Scienture Holdings, Inc. in enhancing its pharmaceutical product portfolio and bringing value to patients and healthcare providers.